P
Peter Martus
Researcher at University of Tübingen
Publications - 563
Citations - 31505
Peter Martus is an academic researcher from University of Tübingen. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 79, co-authored 506 publications receiving 27328 citations. Previous affiliations of Peter Martus include Charité & University of Würzburg.
Papers
More filters
Journal ArticleDOI
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Rolf Sauer,Heinz Becker,Werner Hohenberger,Claus Rödel,Christian Wittekind,Rainer Fietkau,Peter Martus,Jörg Tschmelitsch,Eva Hager,Clemens F. Hess,Torsten Liersch,Heinz Schmidberger,Rudolf Raab +12 more
TL;DR: Preoperative chemoradiotherapy, as compared with postoperative cheMoradi therapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Journal ArticleDOI
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Claus Rödel,Peter Martus,Thomas Papadoupolos,László Füzesi,Martin Klimpfinger,Rainer Fietkau,Torsten Liersch,Werner Hohenberger,Rudolf Raab,Rolf Sauer,Christian Wittekind +10 more
TL;DR: In this exploratory analysis, complete ( TRG 4) and intermediate pathologic response (TRG 2 + 3) suggested improved DFS after preoperative CRT, and TRG assessment should be implemented in pathologic evaluation and prospectively validated in further studies.
Journal ArticleDOI
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Arnfried U. Klingbeil,Markus Schneider,Markus Schneider,Peter Martus,Peter Martus,Franz H. Messerli,Franz H. Messerli,Roland E. Schmieder,Roland E. Schmieder +8 more
TL;DR: A meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass found that angiotensin II receptor antagonists, calcium antagonists, and ACE inhibitors were more effective at reducing left Ventricular mass than were beta-blockers.
Journal ArticleDOI
Reversal of Left Ventricular Hypertrophy in Essential Hypertension: A Meta-analysis of Randomized Double-blind Studies
TL;DR: In this first meta-analysis including only double-blind, randomized, controlled clinical studies, decline in blood pressure, duration of drug treatment, and drug class determined the reductions in left ventricular mass index.
Journal ArticleDOI
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Thomas Berg,Michael von Wagner,Samer Nasser,Christoph Sarrazin,Tobias Heintges,Tilman Gerlach,Peter Buggisch,Tobias Goeser,Jens Rasenack,Gerd R. Pape,Wolfgang Schmidt,Birgit Kallinowski,Hartwig Klinker,Ulrich Spengler,Peter Martus,Ulrich Alshuth,Stefan Zeuzem +16 more
TL;DR: Extended treatment duration generally is not recommended in HCV type 1 infection and should be reserved only for patients with slow virologic response defined as HCV-RNA positive at week 12 but negative at week 24, which is seen in patients with low-level viremia at weeks 12.